Amorfix Life Sciences (TSX: AMF) says it has met all requirements for the development of a novel treatment for amyotrophic lateral sclerosis, or Lou Gehrig’s disease, in preparation for a licensing agreement with Biogen Idec (NASDAQ: BIIB). (BIIB)

Lees meer..